ClinicalTrials.gov
public full text
Public Domain
Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma
The goal of this clinical research study is to learn if the combination of the immunotherapy drugs, CT-011 and rituximab, can help control follicular lymphoma. The safety of this drug combination will also be studied.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma#252981
- Rituximab (anti-CD20 Monoclonal Antibody) As Single First-Line Therapy For Patients With Follicular Lymphoma With A Low Tumor Burden: Clinical And Molecular Evaluation#1148410
- Rituximab + Immunotherapy in Follicular Lymphoma#67886
- Monoclonal Antibody Therapy in Treating Patients With Follicular or Mantle Cell Lymphoma#859051
- Radiation Therapy and Rituximab in Treating Patients With Stage I-II Grade 1 or Grade 2 Follicular Lymphoma#442108
Record · ID 803524
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive